Article Sidebar

PDF (Tiếng Việt)
Published: 2026-07-06
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v203i6.5178
Issue
Vol. 203 No. 6 (2026)
Section
Các bài báo
How to Cite
Thanh, V. H., Hòa, N. T. T., Tờ, T. V., Minh, T. C., & Tuấn Anh, N. (2026). Real-world overall survival of first-line afatinib in EGFR-mutant advanced non–small cell lung cancer at Vietnam National Cancer Hospital. Journal of Medical Research, 203(6), 772-783. https://doi.org/10.52852/tcncyh.v203i6.5178

Real-world overall survival of first-line afatinib in EGFR-mutant advanced non–small cell lung cancer at Vietnam National Cancer Hospital

Vu Ha Thanh, Nguyen Thi Thai Hoa, Ta Van To, Truong Cong Minh, Nguyen Tuan Anh

Main Article Content

Abstract

Afatinib is a second-generation tyrosine kinase inhibitor approved for the treatment of advanced non–small cell lung cancer (NSCLC). This retrospective study included 230 patients with stage IIIC/IV, EGFR-mutant lung adenocarcinoma treated with first-line Afatinib at K Hospital between January 2018 and October 2024; follow-up was conducted until September 2025 to evaluate overall survival (OS) and safety. With a median follow-up of 28.2 months, the median overall survival (mOS) was 27.8 months. No significant difference in OS was observed according to brain metastasis status (p = 0.479), whereas liver metastases were associated with a significantly poorer OS (20.9 vs. 28.8 months; p = 0.025). Patients with common EGFR mutations (L858R, Del19) had longer OS compared to those with uncommon mutations (p < 0.05). No significant difference in OS was observed across different dosing levels. Second-line treatment with Osimertinib resulted in the longest mOS (29.0 months). The most common adverse events were diarrhea and skin toxicity (61.3%), mostly mild to moderate, with no grade ≥ 3 toxicities observed.

Article Details

Keywords

Non – small cell lung cancer, advanced stage, EGFR mutation, Afatinib

References

1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2022;
2. Shi Y, Au JS-K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology. 2014;9(2):154-162.
3. Hirsch FR, Varella-Garcia M, Bunn Jr PA, et al. Epidermal growth factor receptor in non–small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. Journal of clinical oncology. 2003;21(20):3798-3807.
4. Park K, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology. 2016;17(5):577-589.
5. Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology. 2013;31(27):3327-3334.
6. Thái PV, Niên VT, Phương PC, và cs. Kết quả sống thêm toàn bộ của bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IIIc-IV có đột biến EGFR được điều trị bằng afatinib tại Hà Nội. Tạp chí Y học Việt Nam. 2025;550(2).
7. Vân NT, Tú ĐA, Phương TM, Phương VT, Kiên NT. Kết quả điều trị bước 1 bằng afatinib trên bệnh nhân cao tuổi ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến gen EGFR tại Bệnh viện K. Tạp chí Y học Việt Nam. 2025;546(1).
8. Bhandari S, Dunlap N, Kloecker G. Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer. Journal of Thoracic Disease. 2021;13(5):3230.
9. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung cancer. 2015;88(1):108-111.
10. Zhang L, Luo Y, Chen J, et al. Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. Journal of Oncology. 2021;2021(1):8736288.
11. Iuchi T, Shingyoji M, Itakura M, et al. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. International journal of clinical oncology. 2015;20(4):674-679.
12. Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The lancet oncology. 2015;16(2):141-151.
13. Paz-Ares L, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology. 2017;28(2):270-277.
14. Tamura T, Kurishima K, Nakazawa K, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Molecular and clinical oncology. 2015;3(1):217-221.
15. Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung cancer. 2014;86(1):78-84.
16. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The lancet oncology. 2015;16(7):830-838.
17. Tu H-Y, Wu Y-L. Effect of dose adjustments on the safety and efficacy of afatinib in Chinese patients with EGFR-mutated non-small cell lung cancer who participated in the LUX-lung clinical trial program. OncoTargets and therapy. 2020:12539-12547.
18. Ng TL, Camidge DR. AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Annals of translational medicine. 2017;5(Suppl 1):S14.